Dynamic Technology Lab Private Ltd Acquires New Stake in Bruker Corporation $BRKR

Key Points

• Dynamic Technology Lab Private Ltd acquired 28,030 shares of Bruker Corporation during the first quarter, valuing their purchase at approximately $1,170,000.
• Bruker recently reported a 0.32 EPS for the last quarter, missing the consensus estimate of $0.33, with revenues of $797.40 million down 0.4% year-over-year.
• The company declared a quarterly dividend of $0.05 per share, with an ex-dividend date of September 23rd, resulting in a 0.6% yield for shareholders.

Dynamic Technology Lab Private Ltd acquired a new position in Bruker Corporation (NASDAQ:BRKR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 28,030 shares of the medical research company's stock, valued at approximately $1,170,000.

Several other institutional investors have also recently made changes to their positions in the stock. Scientech Research LLC raised its stake in shares of Bruker by 62.8% in the first quarter. Scientech Research LLC now owns 32,728 shares of the medical research company's stock worth $1,366,000 after buying an additional 12,621 shares during the period. Petrus Trust Company LTA bought a new position in shares of Bruker in the first quarter worth about $957,000. Polar Asset Management Partners Inc. raised its stake in shares of Bruker by 370.2% in the first quarter. Polar Asset Management Partners Inc. now owns 80,398 shares of the medical research company's stock worth $3,356,000 after buying an additional 63,298 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Bruker in the first quarter worth about $262,000. Finally, Eventide Asset Management LLC raised its stake in shares of Bruker by 0.6% in the first quarter. Eventide Asset Management LLC now owns 136,400 shares of the medical research company's stock worth $5,695,000 after buying an additional 765 shares during the period. Institutional investors own 79.52% of the company's stock.

Wall Street Analyst Weigh In

BRKR has been the topic of several recent analyst reports. Barclays decreased their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the company a "hold" rating in a research note on Tuesday, August 5th. Citigroup decreased their target price on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Finally, Bank of America decreased their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Bruker presently has a consensus rating of "Hold" and a consensus target price of $51.30.

Bruker Price Performance

NASDAQ:BRKR traded down $1.16 during trading hours on Friday, reaching $30.91. The stock had a trading volume of 2,838,988 shares, compared to its average volume of 4,182,071. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $72.94. The company has a 50 day moving average price of $36.02 and a two-hundred day moving average price of $38.90. The stock has a market capitalization of $4.69 billion, a PE ratio of 59.44, a PEG ratio of 4.45 and a beta of 1.21.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the firm earned $0.52 EPS. The business's revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, sell-side analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker's payout ratio is 38.46%.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 27.30% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.